C

Caliway Biopharmaceuticals Co Ltd
TWSE:6919

Watchlist Manager
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Watchlist
Price: 153.5 TWD
Market Cap: 238.1B TWD

Caliway Biopharmaceuticals Co Ltd
Investor Relations

Caliway Biopharmaceuticals Co. Ltd. offers pharmaceutical services. The company is headquartered in Taipei, New Taipei. The company went IPO on 2022-12-26. The drugs developed by the Company are all small molecule drugs, including CBL-514, CBA-539, CBO-012 and CBF-520. CBL-514 is used for non-surgical local fat reduction, cellulite, Baergen's disease and lipoma and others. The company is in the second clinical stage. CBA-539 is used for pigmentation, whitening and anti-aging, and it is in the non-clinical research stage. CBO-012 is in the non-clinical research stage for degenerative arthritis. CBF-520 is used for central obesity and non-alcoholic fatty liver disease, and it is in the non-clinical research stage. The firm's sales revenue comes from health food, which is sold by agents and distributors, with Taiwan and China as the main sales areas.

Show more
Loading
6919
Taiwan Weighted Index
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Ms. Yufang Ling
CEO and R&D Chief
No Bio Available

Contacts

Address
NEW TAIPEI
Taipei
32F-9, No.99, Section 1, Xintai 5th Road, Xizhi District
Contacts
+886226971355
www.caliway.com.tw